Austin, TX – The Clinical Data Interchange Standards Consortium (CDISC) would like to remind the clinical research community that the FDA Binding Guidance goes into effect next month. Sponsors whose studies start after December 17, 2016 must submit data in FDA-supported formats listed in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies the use of CDISC standards: SDTM, SEND, ADaM and Define-XML as well as Controlled Terminology.
The FDA’s Guidance on Standardized Study Data states... "After the publication of this guidance, all studies with a start date 24 months after the publication date must use the appropriate FDA-supported standards, formats, and terminologies specified in the Catalog (see section II.C) for NDA, ANDA, and certain BLA submissions.”
Implementing CDISC standards offers a number of benefits, including fostering efficiency, improving data quality, enhancing innovation, streamlining processes, increasing the ability to share information among systems and organizations, and reducing costs. Additionally, submitting standardized data helps regulatory reviewers receive, process, review, and archive submissions more effectively.
About CDISC
CDISC is a 501(c)(3) global, non-profit charitable organization that develops clinical research data standards to streamline research and enable connections to healthcare. The CDISC suite of standards supports the complete clinical research lifecycle from protocol through analysis and reporting by allowing data to speak the same language, making the most of the valuable information offered by patients participating in research studies around the globe. Implementing CDISC standards from the start of studies enables Smarter Research to Unlock Cures, saving 70-90% start-up time and ~60% overall in time and resources to conduct clinical research.
CDISC is funded through the generous support of over 400 member organizations, as well as through grants, authorized Education courses and CDISC events. To find out more about how to support CDISC, please visit www.cdisc.org.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.